The Cancer Pharmacology Core Facility (CPCF) provides an analytical laboratory for accurate and sensitive chromatographic determination of chemotherapeutic drugs and some drug metabolites. The facility staff provides the expertise necessary for development of thoroughly validated drug determination methods. The staff also participates in the design of clinical studies of chemotherapeutic agents by specification of sample collection methodology and recommendation of sampling intervals on the basis of expected pharmacokinetic behavior of studied therapeutic agents. The facility determines drugs in dosage formulations as an element of study design in most of the clinical trials in which we participate. The CPCF has an atmospheric pressure ionization triple quadrupole mass spectrometer (API/MS) which was purchased with NIH BRS shared instrument program grant funds. This instrument is very selective and sensitive toward certain categories of small molecules which include many cancer treatment drugs of low molecular weight. This instrument enables us to bring analytical methods into operation sooner than is possible with optical chromatographic detectors. The availability of this instrument within the CPCF has enabled the Cancer Center to attract funding for clinical trials of thalidomide in combination with docetaxel, and OSI-774 in combination with docetaxel. The facility maintains a database of these analytical results, and it conducts pharmacokinetics analysis of those results.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA043703-19
Application #
7599148
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2008-04-01
Budget End
2009-03-31
Support Year
19
Fiscal Year
2008
Total Cost
$159,403
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Anderson, Christian E; Wang, Charlie Y; Gu, Yuning et al. (2018) Regularly incremented phase encoding - MR fingerprinting (RIPE-MRF) for enhanced motion artifact suppression in preclinical cartesian MR fingerprinting. Magn Reson Med 79:2176-2182
Burger, Denis R; Parker, Yvonne; Guinta, Kathryn et al. (2018) PRO 140 Monoclonal Antibody to CCR5 Prevents Acute Xenogeneic Graft-versus-Host Disease in NOD-scid IL-2Rynull Mice. Biol Blood Marrow Transplant 24:260-266
Shi, Xiaojun; Wang, Bingcheng (2018) Caught in the ""Akt"": Cross-talk between EphA2 and EGFR through the Akt-PIKfyve axis maintains cellular sensitivity to EGF. Sci Signal 11:
Tartakoff, Alan Michael; Dulce, David; Landis, Elizabeth (2018) Delayed Encounter of Parental Genomes Can Lead to Aneuploidy in Saccharomyces cerevisiae. Genetics 208:139-151
Gromovsky, Anthony D; Schugar, Rebecca C; Brown, Amanda L et al. (2018) ?-5 Fatty Acid Desaturase FADS1 Impacts Metabolic Disease by Balancing Proinflammatory and Proresolving Lipid Mediators. Arterioscler Thromb Vasc Biol 38:218-231
Ignatz-Hoover, James J; Wang, Victoria; Mackowski, Nathan M et al. (2018) Aberrant GSK3? nuclear localization promotes AML growth and drug resistance. Blood Adv 2:2890-2903
Hubler, Zita; Allimuthu, Dharmaraja; Bederman, Ilya et al. (2018) Accumulation of 8,9-unsaturated sterols drives oligodendrocyte formation and remyelination. Nature 560:372-376
Asthana, Abhishek; Ramakrishnan, Parameswaran; Vicioso, Yorleny et al. (2018) Hexosamine Biosynthetic Pathway Inhibition Leads to AML Cell Differentiation and Cell Death. Mol Cancer Ther 17:2226-2237
Belur Nagaraj, Anil; Kovalenko, Olga; Avelar, Rita et al. (2018) Mitotic Exit Dysfunction through the Deregulation of APC/C Characterizes Cisplatin-Resistant State in Epithelial Ovarian Cancer. Clin Cancer Res 24:4588-4601
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643

Showing the most recent 10 out of 1227 publications